May. 11 at 5:35 PM
$CDXS very high, if not certain.
There are three 'smoking guns' connecting Merck’s publication to Codexis:
The Precise Timing: On May 7, 2026, Merck published an article in the prestigious journal Science regarding the biocatalytic production of Enlicitide Decanoate (the oral PCSK9 drug). Simultaneously, on May 8, 2026, Codexis released its Q1 2026 quarterly report.
Revenue from Tech Transfer: In its financial report, Codexis reported total revenues of
$15.2 million—a spike of over 100% year-over-year. Management explicitly stated that this growth was primarily driven by the Merck Technology Transfer Agreement, signed in late 2025 and fully recognized in the first quarter of 2026.
The Technological Core: Merck’s article highlights the use of a 'tailored suite of enzymes' for drug production. This is exactly the expertise of Codexis and its CodeEvolver platform. The two companies have a history of collaboration on enzymes for other Merck flagship drugs, such as Januvia.
